Search Results

<< Back to podcast list Strategic Partner(s) Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore About Dr. Khaled Abdelrahman " Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. " Dr. Khaled Abdelrahman on the web Twitter PubMed Google Scholar Dr. GPCR About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at The Rockefeller University, where she study’s the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2 -imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at The Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program in Chemical Biology Rockefeller University LinkedIn Dr. GPCR About Madelyn Moore "Madelyn (Maddi) earned her B.S. in Biochemistry from the University of Minnesota-Duluth in 2020. In her time as an undergraduate, Maddi was a researcher in Dr. Amanda Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain and opioid tolerance. From there, she went on to be a research technologist in Dr. Richard Vile's lab at Mayo Clinic where she aided the evaluation of tumor-specific oncolytic viruses. Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT) Graduate Program at the University of Minnesota. Advised by Dr. Lauren Slosky, she is working to understand the mechanism by which a new class of biased allosteric modulators for the neurotensin receptor 1 (NTSR1) act to attenuate the behavioral effects of methamphetamine." Madelyn Moore on the web MPaT PubMed LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Arthur Christopoulos About Dr. Arthur Christopoulos " Arthur Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, Australia. His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease. His work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain and addiction. He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies. Professor Christopoulos has over 360 publications, including in leading international journals such as Nature,Science and Cell, and has delivered over 180 invited presentations. He has served on the Editorial Board of 8 international journals and was a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR). He has also been the recipient of multiple awards, including the John J. Abel Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics; the Rand Medal from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists; the British Pharmacological Society’s Gaddum Memorial Award; the IUPHAR Sir James Black Analytical Pharmacology Lecturer; the GSK Award for Research Excellence and a Doctor of Laws (Honoris Causa) from the University of Athens. Since 2014, Clarivate Analytics have annually named him a Highly Cited Researcher in ‘Pharmacology & Toxicology’, and in 2021 also named him a Highly Cited Researcher in the additional category of ‘Biology & Biochemistry’. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences, in 2018 as a Fellow of the British Pharmacological Society, and in 2021 he was elected a Fellow of the Australian Academy of Science for his seminal contributions to drug discovery. In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. Arthur Christopoulos on the web Monash University Wikipedia Google Scholar LinkedIn Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap Yamina and Arthur from Monash University discussed Arthur's career journey, the importance of hard work, failure, and differentiation in academic and personal lives, and the value of international conferences. They also explored the significance of translating fundamental discoveries into clinical applications, the potential of new drugs, and the unique challenges within universities. Additionally, they discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development, and the potential of involving junior scientists and postdocs in their podcast. Lastly, they touched upon the global challenges of healthcare workforce growth, climate change, and emerging psychiatric disorders, as well as the importance of recording lectures and making pre-lesson materials available to students. Next steps - Yamina will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development and its impact on the field with Yamina. - Yamina will send an invite for a follow-up meeting with Arthur next Saturday at 9 PM. - Arthur and Yamina will prepare for the next meeting, focusing on the concept of biased agonism and discussing Dr. GPCR and the charity status. - Yamina will attempt to book Denise for a future podcast episode. Summary Arthur's Career Journey and Transition to Dean Yamina introduced Arthur to her team and discussed the use of a particular tool for meeting summaries. Arthur shared his career journey from pharmacy to becoming a professor, highlighting the influence of his mentors and the importance of his postdoctoral experience. They discussed the value of hard work, failure, and the significance of differentiation in their personal and academic lives. Towards the end, they focused on Arthur's transition to become Dean and his decision to move from Australia to the United States for a postdoctoral position. Postdoctoral Position, Scientific Dynamics, and New Drug Targets Arthur shared his decision to undertake a postdoctoral position with Nigel Bird's lab in the UK and his experiences of meeting influential figures during his time in the US. He and Yamina discussed the importance of preserving original work, the value of international conferences, and the dynamics between junior and senior scientists in a research environment. They also shared their admiration for the work of a mutual friend and discussed the history of muscarinic receptors, specifically focusing on the role of a compound that Arthur received from Fred. Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's compound, Xanomeline, and the potential of M4 PAM for psychosis. Collaborative Research and Translational Approach Arthur and Yamina from Monash University discussed their collaborative approach to scientific research, emphasizing the benefits of combining their complementary skills and interests. They shared their unconventional approaches to research, including the creation of a critical mass of GPCR researchers in Australia and the initiation of a successful series of conferences. They also discussed the relocation of some university labs to facilitate collaboration and overcome the siloed department structure. Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization. Lastly, Arthur shared three significant moments that shaped his career, including the evolution and impact of analytical pharmacology, particularly highlighting the role of Prism, a data analysis tool. Podcast Format, Team Culture, and Science Yamina and Arthur concluded their discussion and decided to take a short break. They talked about the format and length of their podcast, their professional interests, and their recent successful bid to bring Moderna to their university. They also explored the idea of starting a similar talk show format to 'Between Two Ferns', the importance of maintaining team culture, and the potential health issues among well-known scientists. Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, the importance of knowing when to let go in scientific experiments, and the idea of a panel for building and incubating companies. Arthur's Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid-19 pandemic, his journey as a research fellow in Australia, and his transition to the role of Dean. Arthur shared his insights into the unique grant funding system in Australia, the importance of impact in research, and the challenges of balancing administrative responsibilities with scientific pursuits. He also reflected on his personal health struggles, the growth of his university, and the faculty's successful response to the Covid crisis. The conversation also touched upon Arthur's career decisions, his scientific achievements, and the importance of learning from mistakes and self-confidence. Lastly, they discussed the global challenges of healthcare workforce growth, climate change, and emerging psychiatric disorders, as well as the importance of recording lectures and having pre-lesson materials available to students. Translating Discovery Into Clinical Application Arthur and Yamina discussed the importance of translating fundamental discoveries into clinical applications in their research, highlighting the unique opportunities presented by their location and partnerships with other institutions. They stressed the necessity of making their research goals clearer, avoiding replication, and adopting a more assertive approach in grant applications. They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development in university systems. The conversation highlighted ongoing challenges within universities, including resistance to change and the need to communicate expectations and protect established cultures. Hiring Process, Collaboration, and Education-Focused Initiatives Arthur emphasized the importance of differentiation, impact, and interest in their hiring process and fostering a culture of collaboration. He shared his vision of breaking down barriers and promoting education-focused initiatives, encouraging his team to be innovative and apply their skills to education. Yamina expressed a desire to learn from successful leaders and the importance of recognizing talent and matching it with the needs of a particular project. They also discussed the disruption within the pharmaceutical sector, the importance of workforce development, and the need for maintaining a healthy work-life balance. Lastly, they deliberated on involving junior scientists and postdocs in their podcast and the possibility of writing a book about their experiences in academia. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat Tunaboylu, Antiverse's CEO, has a software engineering and bioinformatics background. Mid-career, he has worked in finance and developed high-frequency trading systems. After switching to biotech, Murat has built cell imaging software and lab robots to accelerate cancer research and automated Thermo Fisher Scientific’s gene synthesis workflows. He has co-founded consultancy and biotech companies Svarlight and Antiverse. His current focus is to realise Antiverse’s mission: engineering the future of drug discovery." Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter Dr. GPCR About Ben Holland "Ben gained his masters in Engineering Science from Oxford, taking a specialisation in information engineering. Following this, he joined an early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development team, pursued international strategic partnerships, managed IP matters, helped establish a manufacturing line in Malaysia and is named as inventor on several patents. He then returned to information engineering and has been working in machine learning for nearly 10 years, applying it to antibody generation, analysis, and property prediction since 2017" Ben Holland on the web Antiverse The Antibody Society YT LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Aaron Sato About this episode In this episode of the Dr. GPCR Podcast , I spoke to Dr. Aaron Sato from Twist Biopharma , a vertical within Twist Bioscience . Aaron is currently the Chief Scientific Officer and VP of Protein Engineering. He earned his Ph.D. at the Massachusetts Institute of Technology, where he studied MHC class II structure-function relationships. His path led him to work in an industry where he assumed various responsibilities and roles in the antibody space. Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics. Dr. Sato published over 30 peer-reviewed papers and contributed to 40 issued patents in the antibody space. During our time together, Aaron and I discussed how using Twist Bioscience’s proprietary technology to manufacture DNA at a scale, the team saw an opportunity to tackle the challenge of identifying novel functional antibodies targeting GPCRs by incorporating these natural binding partners into Twist’s antibody library design. We’d like to extend a special thanks to Twist Biopharma for sponsoring this episode of the Dr. GPCR podcast. Dr. Aaron Sato on the web LinkedIn Twitter Google Scholar Twist Bioscience Twist Biopharma Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

A conversation with Prof. David Hodson on visualizing GLP-1 and GIP receptors in pancreatic islets and brain circuits to advance GPCR-targeted therapies for diabetes and obesity. << Back to podcast list Strategic Partner(s) Visualizing GLP-1 & GIP Receptors in Islets and Brain In this episode, Professor David Hodson discusses how GLP-1 and GIP receptors regulate metabolism across the pancreas and brain, and why visualizing receptor localization and signaling in real tissues is essential for advancing GPCR drug discovery . His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and ligand engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic design. The conversation also highlights the role of interdisciplinary collaboration in accelerating innovation in diabetes and obesity research. Why this matters How receptor distribution in islets and brain circuits shapes incretin hormone drug effects Why visualization tools changed our understanding of GPCR signaling in metabolic tissues What collaborative chemistry enabled in designing receptor-targeted fluorescent ligands The moment when structural and imaging evidence clarified unexpected glucagon-derived peptide behavior How future metabolic therapies may evolve based on receptor cross-talk and tissue-specific engagement Who should listen Navigated complex datasets where interpretation depended on biological context Balanced innovation with the need for reproducible, well-controlled functional assays Worked across disciplines where chemistry, pharmacology, and physiology converge Questioned how drug action differs in real tissues vs. recombinant cell lines …this episode will resonate. About David Hodson Prof. David Hodson is the Robert Turner Professor of Diabetic Medicine at the University of Oxford , working within the Oxford Centre for Diabetes, Endocrinology and Metabolism. Originally trained as a Veterinary Surgeon , he completed postdoctoral research at the CNRS in Montpellier before establishing his independent laboratory at Imperial College London as a Diabetes UK RD Lawrence Fellow. He later served as Professor of Cellular Metabolism and Institute Deputy Director at the University of Birmingham. His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within complex tissues, with direct relevance to type 2 diabetes and obesity therapy . David Hodson on the Web Radcliffe Department of Medicine Islet Biology Lab University of Birmingham Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Katarzyna Marcinkiewicz About Dr. Katarzyna Marcinkiewicz "Katarzyna is a Senior Editor at Nature Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural and Molecular Biology and Nature Biotechnology. She obtained her Ph.D. from Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer. During her postdoctoral training at New York University School of Medicine, her research focused on cellular senescence. Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus on membrane proteins and protein folding." Dr. Katarzyna Marcinkiewicz on the web LinkedIn Nature The Spectator Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Qing Fan About this episode Dr. Fan is currently an associate professor of Pharmacology and Pathology and Cell Biology at Columbia University in NYC. Qing is a structural biologist interested in the molecular mechanisms controlling how class C GPCRs transmit signals. She obtained her bachelor's, master and doctoral degrees at Harvard University and completed her postdoctoral training with Dr. Hendrickson at Columbia University. Join us and learn more about Qing's work and how we powered through a technical issue during the interview. Dr. Qing Fan on the web Fan Lab Dr. Fan at Columbia University Research Gate LinkedIn Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Nyla Naim, Dr. Michael Lemieux & Dr. Jason Nasse About Dr. Nyla Naim Nyla is a Senior Scientist on the Scientific Support Team at Addgene . She received her Ph.D. at the University of Pittsburgh and continued her postdoctoral research at the University of Vermont studying cellular signaling, biosensors, and optogenetics. Nyla supports biomedical research by connecting researchers with resources and promoting reproducible science. Dr. Nyla Naim on the web LinkedIn Dr. GPCR Ecosystem About Dr. Michael Lemieux ''My name is Michael (Mike) Lemieux and I am a Connecticut native. I completed my Ph.D. in molecular and cell biology at UConn and then joined Addgene as a Quality Control Scientist in 2015. Since then I transitioned into a Scientific Support role to leverage my passion for helping people! Beyond my interest in science, I am a strong advocate for graduate education reform and I love to write.'' Dr. Michael Lemieux on the web Addgene Blog Dr. GPCR Ecosystem About Dr. Jason Nasse Dr. Jason Nasse is a senior scientist at Addgene specializing in the use of AAV viral vectors. He obtained his Ph.D. in Neuroscience from Ohio State University focusing on synaptic plasticity and adrenergic receptor modulation of both pre-and postsynaptic properties. By taking a very non-traditional path to obtain a Ph.D. Dr. Nasse has had the opportunity to experience how science is performed across different sectors and around the country. Prior to his role at Addgene, Jason held roles in academia, big pharma, and non-profit research organizations. Dr. Jason Nasse on the web LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Aylin Hanyaloglu About Dr. Aylin Hanyaloglu Dr. Aylin Hanyaloglu has been a Principal Investigator at Imperial College London since 2007. She received her BSc in Human Biology from King’s College London in 1997, and while her Ph.D. commenced at the MRC Human Reproductive Sciences Centre, Edinburgh, a move to Perth, Australia resulted in her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western Australia. Dr. Hanyaloglu undertook her postdoctoral training at the University of California, San Francisco with Professor Mark von Zastrow where she identified novel core cellular machinery critical for G protein-coupled receptor trafficking and signaling. Her research focuses on understanding the fundamental cell biological mechanisms regulating GPCR activity, including spatial control of GPCR signaling and receptor crosstalk, and applying these mechanisms for distinct GPCRs in diverse physiological and pathophysiological systems, with particular focus on women's health, pregnancy, and nutrient sensing in the gut. Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes UK, Wellcome Trust, and the Medical Research Council. Dr. Aylin Hanyaloglu on the web LinkedIn Researchgate Twitter Imperial College London Elsevier Loop Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Kathleen Caron About Kathleen M. Caron Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department currently ranked 1st in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health. Kathleen M. Caron on the web Lab Website Twitter Pubmed Google Scholar Orcid Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. David Sykes About Dr. David Sykes " David Andrew Sykes, BSc Hons Pharmacology, MSc Molecular Biology and Biochemistry, PhD in Molecular Pharmacology & Drug Discovery. David has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. In 2014 David joined the University of Nottingham and began a part-time PhD in Molecular Pharmacology and Drug Discovery that he was awarded in 2020. During this period David has made a significant contribution to the understanding of agonist/ antagonist GPCR kinetic determinants in an area of growing scientific interest. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically designed to assess the kinetics of unlabelled compounds (and chemical fragments) and the use of purified receptor/ effector proteins as tools for drug discovery. " Dr. David Sykes on the web Veprintsev Lab ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Yamina Berchiche About this episode In this Episode 0 of the brand new Dr. GPCR podcast , your host and founder, Dr. Yamina Berchiche introduces the very first podcast dedicated to GPCRs researcher and their work. This podcast is part of the Dr. GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well as suppliers working on GPCRs by providing opportunities to connect, share, form trusting partnerships, grow, and thrive together to accelerate GPCR drug discovery and improve human health. Dr. Yamina Berchiche on the web - Website - LinkedIn - PubMed - Twitter - Facebook - Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Terry Hébert About this episode Dr. Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University. Much of his work is based on GPCR signaling in the context to cardiovascular diseases. In this special episode of the Dr.GPCR podcast , we re-connected with Dr. Terry Hebert to chat about how he and his team has been adapting to the new reality of working remotely. Terry tells us about the importance of adapting, communicating, and being mindful of those around us. Dr. Terry Hébert on the web Terry Hébert | Institute of Health Sciences Education Hébert Lab LinkedIn Hébert Lab The GPCR Consortium PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Dr. Eric Trinquet discusses the science and story behind pH Sense, Revvity’s innovative GPCR internalization assay, and his journey in GPCR product R&D. << Back to podcast list Strategic Partner(s) From Rare Earth Probes to Internalization Assays: The pHSense Story with Dr. Eric Trinquet What does it take to design a breakthrough GPCR assay—from idea to industrial impact? In this special episode, Dr. Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation for tracking GPCR internalization. With a career spanning two decades at the intersection of fluorescence chemistry, functional assays, and product development, Eric takes us through the highs, failures, and scientific “aha” moments that shaped tools like the IP-One kit, Tag-lite, and now, pH Sense. If you’ve ever used HTRF or wondered what goes into making a product worthy of your next experiment, this is your backstage pass. You’ll hear what truly makes a reagent successful—and why academic–industry collaborations are essential for advancing GPCR research. ⸻ Inside This Episode How Eric and his team reimagined rare earth complexes to develop pH-sensitive probes with tunable brightness and lifetime. Why pH Sense enables high-throughput, no-wash tracking of GPCR internalization—even at endogenous expression levels. What shifted the team’s strategy from traditional calcium assays to IP1 accumulation—and why it mattered for Gq-coupled receptors. How collaborations with David Parker and Jean-Philippe Pin accelerated both probe chemistry and biological validation. What it felt like to see the first dose-response curves in native beta cells—and why that moment changed the trajectory of the project. Why the commercialization of a reagent is not the end, but the beginning of a feedback-driven innovation cycle. ⸻ Why It Might Hit Home If you’ve ever: Wrestled with unreliable endpoint assays or cumbersome radioactive protocols, Pushed for more physiologically relevant systems and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development, Or felt the thrill of seeing a tool you built drive real biological insight… …this episode will resonate. ⸻ About the Guest Dr. Eric Trinquet is Head of R&D for Life Sciences Reagents at Revvity, where he leads innovation in biochemical and cell-based assay platforms. With a foundational career at Cisbio Bioassays—later acquired by Revvity—Eric played a pivotal role in bringing technologies like HTRF, the IP-One kit, and the Tag-lite platform into widespread use. Originally trained as a physicist with a strong interest in photophysics and fluorescence chemistry, Eric transitioned into the GPCR field through hands-on assay development. His passion lies in turning cutting-edge probe chemistry into robust, scalable tools for drug discovery and basic research. What drives him? A mix of scientific curiosity, a tolerance for failure, and a commitment to delivering real-world impact—one product at a time. ⸻ More about Revvity pHSense Reagents GPCR Reagents Revvity on Dr. GPCR Dr. GPCR X Revvity Collaboration ⸻ Want more like this? Join the Dr. GPCR Premium Ecosystem for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical tools to accelerate your research or career. 👥 Build connections. 🧪 Get insights. 🎧 Stay ahead. 👉 Join now Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) GPCR location matters with Dr. Gabriele Kockelkoren About Gabriele Kockelkoren I have a strong background in both physics and molecular biology and, accordingly, I strive in interdisciplinary environments. After completing a cum laude BSc. and MSc. in Nanobiology at the Technical University of Delft in The Netherlands, I pursued a PhD at the University of Copenhagen under the supervision of Prof. Dimitrios Stamou. In my PhD, I studied the nanoscale spatial organization of G protein-coupled receptors (GPCRs) at the plasma membrane of living cells. Importantly, my work revealed heterogeneous spatial patterns of receptor density and activation, that are modulated in a drug-dependent manner. These findings identify nanoscale GPCR spatial organization as an integral element of their activity and signaling. Currently, I am a Postdoctoral Fellow in the lab of Prof. Alice Ting developing programmable receptors for molecular sensing and controlling cellular behaviour. Gabriele Kockelkoren on the web Stanford University X LinkedIn Google Scholar ORCID ResearchGate Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Stephane Angers About Dr. Stephane Angers Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D. from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier . His thesis work led to the development and application of light energy transfer methodology to study protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under Dr. Randall T. Moon , where he identified and characterized novel components of the Wnt signaling pathway and a new class of E3 ubiquitin ligases . In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, and human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development of these molecules. In September 2021, Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists. Dr. Stephane Angers on the web Angers Lab The Donnelly Centre Twitter Dr. GPCR Ecosystem LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Shivani Sachdev About Dr. Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain. She received her undergraduate degree in Biotechnology from KIIT University in India. She subsequently joined Professor Mark Connor's laboratory at Macquarie University in Australia. Dr. Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid receptors. She is also very active within the pharmacology community and currently serves on the editorial board of the British Journal of Pharmacology. Given her expertise in GPCR pharmacology and scientific communication, she is poised to make valuable contributions to the field and expand our understanding of GPCR signaling." Dr. Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Gregory Tall About Dr. Gregory Tall " Dr. Gregory Tall earned his Ph.D. in Biomedical Sciences from U.T. Southwestern Medical Center with Bruce Horazdovsky, Ph.D. They worked on the interactome of yeast and mammalian Rab5 homologs including identification of Rab5 GEFs. In 2000, Dr. Tall moved upstairs to conduct his postdoctoral work on heterotrimeric G proteins and the novel interactor, Ric-8 with Alfred Gilman, M.D. Ph.D. In 2007, Dr. Tall joined the faculty in the Department of Pharmacology and Physiology at the University of Rochester Medical Center, there establishing his lab and major research directions. Dr. Tall moved to the University of Michigan in 2016 as an Associate Professor of Pharmacology and is a current active member of the department. The current goals of the Tall lab are to understand the basic mechanism by which Ric-8 proteins fold all heterotrimeric G protein alpha subunits, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays to explore the mechanisms of action of the 33-member adhesion GPCR family or Family B2 GPCRs. We found that adhesion GPCRs are activated by a tethered peptide agonist mechanism that differed from the common example known at the time, protease activated receptors (PARs). PARs have an N-terminal leader sequence that is clipped by exogenous proteases to reveal a new N-terminus that serves as the tethered agonist. Adhesion GPCRs pre-cleave themselves and the two resultant fragments of the receptor remain together to conceal the tethered peptide agonist. Mechanical dissociation of the two fragments aided by protein binding ligands and cell movement serves to decrypt the tethered agonist for binding to its orthosteric site. Our current goals are to explore this mechanism in detail and to understand how it may happen for the 33 adhesion GPCRs in complex physiological contexts…one being our discovery that GPR56 is the platelet receptor that senses collagen and shear force to initiate the platelet activation program. Dr. Tall has been continuously funded by the NIH since receiving an early RO1 award at Rochester. He has continued funding at Michigan through the MIRA R35 program. Dr. Tall has presented his work at 59 invited seminars including national and international meetings and academic departmental seminars. " Dr. Gregory Tall on the web The Tall Lab University of Michigan Google Scholar Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. J. Silvio Gutkind About this episode Have you had moments that defined your scientific tastes? For Dr. J Silvio Gutkind, a class on oncogenes and his interests for GPCRs helped shape his scientific interests. These took him from the University of Buenos Aires in Argentina to UC San Diego and through the National Institutes of Health in Bethesda, Maryland. In this episode, Silvio discusses G protein signaling in the context of cancer, immunotherapies, and combination therapies that could help improve patients’ lives. Dr. J. Silvio Gutkind on the web Dr. J Silvio Gutkind on LinkedIn Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Gutkind Lab on Pubmed Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Terry Kenakin About Dr. Terry Kenakin After obtaining a BSc in chemistry at the University of Alberta Edmonton Canada, Terry received his Ph.D. in Pharmacology from the University of Alberta, Department of Chemistry, Canada. Dr. Kenakin then moved to the UK, where he did a post-doctoral fellowship in University College London with Sir James Black. His next stop took him to Burroughs-Wellcome (BW) in Research Triangle Park (RTP) in North Carolina USA. After 7 years at BW, Dr. Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome , and finally GlaxoSmithKline . Since 2011, Terry works at the Department of Pharmacology at the University of North Carolina School of Medicine Chapel Hill NC. His interests are in receptor pharmacology, allosteric protein function, and drug discovery. Dr. Terry Kenakin on the web LinkedIn UNC Department of Pharmacology Amazon ResearchGate Pubmed . Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Brian Shoichet About Dr. Brian Shoichet BSc in Chemistry from MIT, Ph.D. with Tack Kuntz at UCSF; Postdoc with Brian Matthews in protein stability-activity tradeoffs, crystallography; started my independent lab at Northwestern University Medical School (1996) was recruited back to UCSF in 2003. Dr. Brian Shoichet on the web Google Scholar Shoichet Lab Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Sri Kosuri About Dr. Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology, functional genomics, and bioinformatics over the last 20 years. He is passionate about developing more rational ways to understand and engineer biology. Sri is a co-founder at Octant and an Associate Professor at UCLA in the Chemistry and Biochemistry Department. His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry, human genetic variation, gene regulation, chemical biology, synthetic biology, and functional genomics. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of Joule Unlimited, an engineered algal biofuel company. He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering at MIT and BS in Bioengineering at UC Berkeley. Sri is originally from New Jersey, Philadelphia, and Kansas and was born in North Carolina. He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr. Sri Kosuri on the web Octant Kosuri Lab Twitter LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Mark Schmeizl About Mark Schmeizl Mark leverages 30 years in various life science laboratories & commercial roles with his network of VC & PE contacts to help senior-level life science executives identify new opportunities. He has successfully built numerous global life science, leadership teams, & works closely with both clients & candidates to understand their unique needs & culture. Mark believes professional placement should be about matching talented people with companies where they will thrive, “when the match is right, the results are astonishing.” Dr. Mark Schmeizl on the web Website LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Robert Laprairie About Dr. Robert Laprairie Dr. Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development in the College of Pharmacy and Nutrition at the University of Saskatchewan. The focus of his research is the molecular pharmacology of cannabinoids and cannabinoid receptors. He was the 2018 and 2021 recipient of the Young Investigator of the Year Awards from the British Pharmacological Society and International Cannabinoid Research Society (ICRS), respectively. In 2019 he became the Director of Education for the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and now also serves as the organization’s President. Dr. Robert Laprairie on the web University of Saskatchewan Twitter Instagram ResearchGate Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Sai Prasad Pydi About Dr. Sai Prasad Pydi Dr. Sai Prasad Pydi obtained his Ph.D. from the University of Manitoba – Canada, where he was introduced to G protein-coupled receptors (GPCRs) by Prof. Prashen Chelikani . His doctoral research focused on the structural and functional characterization of bitter taste receptors (T2Rs). In 2014, Dr. Pydi joined Dr. Jurgen Wess’s lab at the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) - NIH, USA as a postdoctoral fellow and trained on understanding the physiological role of GPCR signaling and beta-arrestins in diabetes and obesity. In February 2021, Dr. Pydi joined BSBE department at IIT-Kanpur. The main target of Dr. Pydi's laboratory is to develop GPCR-based drugs for the treatment of obesity and Type 2 Diabetes (T2D) by exploring metabolically important signaling pathways in immune cells and insulin-sensitive tissues (liver, pancreas, skeletal muscle, adipose tissue, and brain). His laboratory uses knock-out and transgenic mouse models, along with different cell culture systems, to understand the role of immune cell GPCRs and their cross-talk with other insulin-sensitive tissues regulating glucose and lipid metabolism. Dr. Sai Prasad Pydi on the web Molecular Metabolism & Cell Signaling Laboratory Website Twitter.com Research Gate PubMed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Paul J. Gasser About Dr. Paul J. Gasser " I received my BS and MS in Zoology & Physiology at the University of Wyoming, where I studied signaling processes involved in light-induced regulation of melatonin synthesis in the rainbow trout pineal organ, a directly photosensitive endocrine organ. I received my PhD in Biology at Arizona State University, where I worked in the lab of Miles Orchinik, studying cellular mechanisms underlying non-genomic actions of corticosteroid hormones. My postdoctoral work, conducted at the University of Bristol, UK, in Christopher Lowry's lab, examined the role of organic cation transporter 3 (OCT3) in the regulation of monoamine signaling in the brain. I joined the faculty of Biomedical Sciences at Marquette in 2007. I teach undergraduate Biochemistry and a variety of graduate neuroscience courses. Research in my lab is currently focused on understanding the signal transduction pathways activated by beta-adrenergic receptors localized to the inner nuclear membrane and their role in the regulation of gene expression." Dr. Paul J. Gasser on the web Gasser Lab Marquette University Google Scholar ResearchGate LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Jean Martin Beaulieu About Dr. Jean Martin Beaulieu Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University. Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents. Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs. In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology. Dr. Jean Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Catherine Demery shares how she found clarity and purpose in academic opioid research. From her early doubts to designing preclinical models of fentanyl and xylazine overdose, she reflects on staying in academia, building translational experiments, and using real-world data to drive impactful science in the GPCR research community. << Back to podcast list Strategic Partner(s) Xylazine, Fentanyl, and the Fight for Breath with Catherine Demery Two drugs. Two different mechanisms. One deadly outcome. Fentanyl and xylazine are pushing the opioid crisis into dangerous new territory, and Catherine Demery is on the front lines of the science trying to stop it. In this gripping conversation, Catherine, a PhD candidate at the University of Michigan, shares how personal loss and an unconventional career path—industry chemist, NIH researcher, and now GPCR pharmacologist—led her to investigate how these drugs shut down breathing in different ways. Her research combines cutting-edge GPCR signaling studies with real-time public health data from Michigan’s Red Project, revealing how fentanyl slows inhalation, xylazine prolongs exhalation, and together they drop heart rate to dangerous lows. And while users aren’t asking for xylazine, dealers are lacing it into the supply—driving overdose deaths higher. Why This Matters Fentanyl : Potent synthetic opioid that decreases inhalation rate. Xylazine : Veterinary sedative that prolongs exhalation and induces bradycardia—acting through alpha-2 adrenergic, not opioid, receptors. The Combo : Not just additive—lethal. Street Data : Xylazine-laced fentanyl in Michigan has jumped 30–60% in recent years. What You’ll Learn in This Episode How industry lab experience builds the discipline needed for academic research. Why xylazine is an emerging overdose threat and how it differs mechanistically from opioids. The methods used to measure respiratory depression in live models. How loss and lived experience can sharpen scientific focus. The role of public health programs in informing lab research. How GPCR pharmacology connects molecular insights to real-world interventions. Who Should Listen This episode is especially relevant for: GPCR drug discovery scientists Respiratory pharmacologists Addiction researchers Public health professionals Early-career scientists navigating non-linear paths About Catherine Demery Catherine Demery didn’t set out to be on the front lines of the opioid crisis. After earning her undergraduate degree in biochemistry from the University of Michigan, she deferred pharmacy school, unsure if that path felt right. Instead, she went hands-on—working as an analytical chemist in a GLP/GMP-regulated CRO, where precision and discipline became second nature. That led her to a master’s in pharmacogenomics at Manchester University, igniting her fascination with how genetics and drugs interact. Her next stop: the NIH, studying the immunology of pregnancy. But loss has a way of sharpening focus—friends lost to overdose brought the opioid epidemic into painful clarity. Catherine decided to act where she could make the biggest difference: in the lab. Today, as a PhD candidate in the labs of Dr. John Traynor and Dr. Jessica Anand at the University of Michigan, Catherine investigates how fentanyl and xylazine shut down breathing through different mechanisms—work that blends receptor pharmacology, preclinical models, and public health data to tackle one of the most urgent challenges in addiction science. Catherine Demery on the web LinkedIn Google Scholar University of Michigan 🎧 Listen now and see how one scientist is turning molecules into a mission, bridging the gap between receptor pharmacology and the urgent fight to save lives in the opioid epidemic. __________ Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR training program , GPCR podcast , opioid pharmacology , xylazine research , mu opioid receptor , pharmacogenomics , fentanyl epidemic , preclinical pharmacology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Bryan Roth About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Martin Audet About Dr. Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke. He is the head of the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural biology of G Protein-Coupled Receptors and passive transporters. Strong education with a Doctor of Philosophy (Ph.D.) in biochemistry under the supervision of Michel Bouvier at Université de Montréal, followed by a Postdoctoral Fellow at Scripps Research in San Diego and the University of Southern California in Los Angeles as a member of Raymond Stevens group. Dr. Martin Audet on the web LinkedIn Twitter Sherbrooke University Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>